Angel Concha's research while affiliated with Complejo Hospitalario Universitario a Coruña (CHUAC) and other places

... While any microbiome-related field of study is of interest, our specific focus lies within the biomedical sphere, particularly in cancer research. This paper, in particular, centres on the examination of formalin-fixed paraffin-embedded (FFPE) microbiome samples from colorectal cancer (CRC) patients (Conde-Pérez et al., 2023). Sequencing of these samples was conducted using the 16S Amplicon Metagenomic Sequencing technique, a next-generation, highthroughput methodology that emphasizes amplifying specific, short, targeted regions known as amplicons. ...

... Consequently, the clusters were grouped based on the expression of distinct cell type markers, leading to the classi cation of cells into four clusters (epithelial cells, endothelial cells, immune cells, and broblasts). A similar analytical pipeline was applied to immune cells, where the identi cation of immune cell types was achieved by matching each cluster-speci c gene set with known signature genes of cell populations reported in previous literature [17][18][19][20][21][22][23][24] . ...

... Their results were validated by Diaz-Mercedes et al., observing a mean TTL in pN0 of 433.6 copies/µL, pN1 of 35,782.6 copies/µL, and pN2 of 144,651.8 copies/µL [14,27,63]. In our study, the tumour burden in the LNs of pT1 CRC with pN0 determined with H&E was lower, with a median of 990 copies/µL (mean 1540.6 copies/µL), while pN1 cases had a median of 5000 copies/µL (mean 9241 copies/µL). ...

... The human CBLL1 gene encodes the Hakai protein. It has been reported that the Hakai protein is highly expressed in colon and gastric cancer tissues compared to normal epithelial tissues [20,27]. Furthermore, Hakai expression progressively increases in adenoma (non-malignant tissue) and in different TNM stages (I-IV) of colon cancer patients compared to adjacent colon healthy tissues, highlighting the potential of Hakai as a biomarker for CRC progression [22]. ...

... FAP is abundant in the stroma which is related to tumor staging and aggressiveness in BCa patients. According to Gil et al. [64], FAP + CAFs have been associated with immune-cold TMEs characterized by inadequate infiltration of CD8 + T-cells and a significant loss of human leukocyte antigen expression on tumor cells. The deposition of a highly crosslinked ECM, which serves as a physical barrier to exclude lymphocytes in peritumour regions, is another factor that FAP + CAFs contribute to poor CD8 + T cell infiltration [65]. ...

... The response of patients with HER2-positive BC to HER2-targeted therapy is significant; however, the response is not universal, and a proportion of patients with HER2-positive BC do not respond [5][6][7]. In addition, conflicting data exist in the literature regarding the relationship between anti-HER2 therapeutic response and HER2 protein expression or HER2 ISH parameters, including HER2 and centromeric 17 (CEP17) copy numbers and HER2 /CEP17 copy number ratios, in both adjuvant and neoadjuvant settings [7][8][9][10][11][12][13][14][15][16]. Neoadjuvant HER2-directed therapy provides an opportunity to determine the in vivo response to therapy, as patients who achieve a pathological complete response (pCR) can anticipate a higher probability of avoiding both disease recurrence and death from BC [17][18][19]. ...

... Briefly, FTO inhibitors (FTOi) include rhein [86], MO-I-500 [87], MA/MA2 [88], fluorescein [89], R-2HG [90], FB23/FB23-2 [91], entacapone [92], CS1/CS2 [93], Dac51 [94], FTO-4 [95], FTO-43 [96], 18097 [97], and C6 [98], while ALKBH5 inhibitors (ALKBH5i) include IOX1 [99], MV1035 [100], ALK04 [101], Ena15 [102], 20m [103], and DDO-2728 [104]. Finally, the development of drugs aiming to target other m 6 A effector proteins and epitranscriptomic marks is still ongoing, with focus on the inhibition of HAKAI [105] and METTL1 [106], respectively. ...

... The proportion of HER2-positive cases in 11 local laboratories was 12.0%, which is similar to the positivity rate (13%) of another Chinese study [13]. However, it is lower than those of the ToGA study (IHC 3+ or IHC 2+/FISH+: 16.0%) and the Spanish results [20] of the HER-EAGLE study (14.1%). These apparent discrepancies between Chinese studies and other two studies may be due to differences in patient characteristics, in particular the Lauren classification and the location of the tumor. ...

... However, cancer cells differ from normal cells in many aspects, including altered expression levels and functional states of mitochondrial Hsp90 and TRAP1 (102,103). Many cancer cells express higher levels of mitochondrial Hsp90 and TRAP1, upregulate the associated signaling pathways and depend on them for survival, (e.g. ...

... Doxorubicin (DOX), a precursor of anthracyclines, is the most extensively used, beneficial, and successful antineoplastic agent. It is derived from a gram-positive bacteria called Streptomyces peucetius [7][8][9] to treat a variety of malignancies, including breast cancer and lymphoma. However, its therapeutic application is restricted due to its cardiotoxic effects [10]. ...